Crossmark

Proportion of CD34+CD38−CD123+ Leukemia Stem Cells at Diagnosis Varies in ELN Risk Groups and an Emerging Novel Marker for Prognosticating the Intermediate Risk patients of Acute Myeloid Leukemia: A Prospective Study

Crossref DOI link: https://doi.org/10.1007/s12288-020-01383-9

Published Online: 2021-01-03

Published Print: 2021-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mishra, Priyanka

Tyagi, Seema

Sharma, Rahul

Halder, Rohan

Pati, Hara P.

Saxena, Renu

Mahapatra, Manoranjan
License Information

Text and Data Mining valid from 2021-01-03

Version of Record valid from 2021-01-03
More Information

Article History

Received: 21 August 2020

Accepted: 10 November 2020

First Online: 3 January 2021

Compliance with Ethical Standards

:

: The authors declare that they have no competing interest.

: The study was approved by the Institute Ethics Committee (IEC).

: All the authors consent to publish the article in Indexed journal. The article has not been sent to any other journal for publication at the same time.

Document is current

Any future updates will be listed below